PMID- 17322105
OWN - NLM
STAT- MEDLINE
DCOM- 20070516
LR  - 20091119
IS  - 1066-5099 (Print)
IS  - 1066-5099 (Linking)
VI  - 25
IP  - 5
DP  - 2007 May
TI  - Analyses of very early hemopoietic regeneration after bone marrow 
      transplantation: comparison of intravenous and intrabone marrow routes.
PG  - 1186-94
AB  - In bone marrow transplantation (BMT), bone marrow cells (BMCs) have traditionally 
      been injected intravenously. However, remarkable advantages of BMT via the 
      intra-bone-marrow (IBM) route (IBM-BMT) over the intravenous route (IV-BMT) have 
      been recently documented by several laboratories. To clarify the mechanisms 
      underlying these advantages, we analyzed the kinetics of hemopoietic regeneration 
      after IBM-BMT or IV-BMT in normal strains of mice. At the site of the direct 
      injection of BMCs, significantly higher numbers of donor-derived cells in total 
      and of c-kit(+) cells were observed at 2 through 6 days after IBM-BMT. In 
      parallel, significantly higher numbers of colony-forming units in spleen were 
      obtained from the site of BMC injection. During this early period, higher 
      accumulations of both hemopoietic cells and stromal cells were observed at the 
      site of BMC injection by the IBM-BMT route. The production of chemotactic 
      factors, which can promote the migration of a BM stromal cell line, was observed 
      in BMCs obtained from irradiated mice as early as 4 hours after irradiation, and 
      the production lasted for at least 4 days. In contrast, sera collected from the 
      irradiated mice showed no chemotactic activity, indicating that donor BM stromal 
      cells that entered systemic circulation cannot home effectively into recipient 
      bone cavity. These results strongly suggest that the concomitant regeneration of 
      microenvironmental and hemopoietic compartments in the marrow (direct interaction 
      between them at the site of injection) contributes to the advantages of IBM-BMT 
      over IV-BMT. Disclosure of potential conflicts of interest is found at the end of 
      this article.
FAU - Li, Qing
AU  - Li Q
AD  - First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, 
      Moriguchi City, Osaka 570-8506, Japan.
FAU - Hisha, Hiroko
AU  - Hisha H
FAU - Yasumizu, Ryoji
AU  - Yasumizu R
FAU - Fan, Tian-Xue
AU  - Fan TX
FAU - Yang, Guo-Xiang
AU  - Yang GX
FAU - Li, Qiang
AU  - Li Q
FAU - Cui, Yun-Ze
AU  - Cui YZ
FAU - Wang, Xiao-Li
AU  - Wang XL
FAU - Song, Chang-Ye
AU  - Song CY
FAU - Okazaki, Satoshi
AU  - Okazaki S
FAU - Mizokami, Tomomi
AU  - Mizokami T
FAU - Cui, Wen-Hao
AU  - Cui WH
FAU - Guo, Kequan
AU  - Guo K
FAU - Li, Ming
AU  - Li M
FAU - Feng, Wei
AU  - Feng W
FAU - Katou, Junko
AU  - Katou J
FAU - Ikehara, Susumu
AU  - Ikehara S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070222
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
RN  - 0 (Antigens, CD34)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
SB  - IM
MH  - Animals
MH  - Antigens, CD34/metabolism
MH  - *Bone Marrow Transplantation
MH  - Cell Movement
MH  - Colony-Forming Units Assay
MH  - Drug Administration Routes
MH  - Female
MH  - Granulocytes/cytology
MH  - Hematopoiesis/*physiology
MH  - Kinetics
MH  - Lymphocytes/cytology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Proto-Oncogene Proteins c-kit/metabolism
MH  - *Regeneration
MH  - Stromal Cells/cytology
EDAT- 2007/02/27 09:00
MHDA- 2007/05/17 09:00
CRDT- 2007/02/27 09:00
PHST- 2007/02/27 09:00 [pubmed]
PHST- 2007/05/17 09:00 [medline]
PHST- 2007/02/27 09:00 [entrez]
AID - 2006-0354 [pii]
AID - 10.1634/stemcells.2006-0354 [doi]
PST - ppublish
SO  - Stem Cells. 2007 May;25(5):1186-94. doi: 10.1634/stemcells.2006-0354. Epub 2007 
      Feb 22.